Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001683168-23-002086
Filing Date
2023-03-31
Accepted
2023-03-31 17:04:13
Documents
50
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K cns_i10k-2022.htm   iXBRL 10-K 987835
2 CONSENT cns_ex2301.htm EX-23.1 2066
3 CERTIFICATION BY OFFICER cns_ex3101.htm EX-31.1 9792
4 CERTIFICATION BY OFFICER cns_ex3102.htm EX-31.2 9722
5 CERTIFICATION OF OFFICER cns_ex3201.htm EX-32.1 3564
6 CERTIFICATION OF OFFICER cns_ex3202.htm EX-32.2 3350
  Complete submission text file 0001683168-23-002086.txt   4427771

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE cnsp-20221231.xsd EX-101.SCH 28467
8 XBRL CALCULATION FILE cnsp-20221231_cal.xml EX-101.CAL 29538
9 XBRL DEFINITION FILE cnsp-20221231_def.xml EX-101.DEF 127004
10 XBRL LABEL FILE cnsp-20221231_lab.xml EX-101.LAB 263218
11 XBRL PRESENTATION FILE cnsp-20221231_pre.xml EX-101.PRE 210826
44 EXTRACTED XBRL INSTANCE DOCUMENT cns_i10k-2022_htm.xml XML 633666
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

EIN.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-39126 | Film No.: 23788991
SIC: 2834 Pharmaceutical Preparations